RNS Number : 7366C Renalytix AI PLC 22 June 2021 The following amendment(s) has been made to the ' Director/PDMR Dealing ' announcement released on 22 June 2021 at 10:57 under RNS No 7062C. The price of 113.5 pence per share was incorrect and has been amended to 1135 pence per share.
RNS Number : 7062C Renalytix AI PLC 22 June 2021 Renalytix AI plc ("Renalytix" or the "Company") Director/PDMR Dealing The Company was informed that today, Christopher Mills , a non-executive director and interim Chairman, completed the sale of 17,000 ordinary shares of 0.25 pence each
RNS Number : 9139B Renalytix AI PLC 15 June 2021 Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021 NEW YORK , June 15, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) ("Renalytix" or the "Company") today reported financial results for the quarter and nine months
RNS Number : 4033B Renalytix AI PLC 10 June 2021 Renalytix AI plc (" Renalytix " or the " Company ") Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update Announces Change of Auditor to Ernst & Young LLP NEW YORK , June 10, 2021 - Renalytix AI
RNS Number : 9511A Renalytix AI PLC 07 June 2021 Renalytix AI plc (" Renalytix " or the " Company ") Leadership additions announced to support expanding US Government and Healthcare Provider KidneyIntelX Deployment Enabling expertise in sales, population health and value-driven care models
RNS Number : 6483A Renalytix AI PLC 03 June 2021 Renalytix AI plc (" Renalytix " or the " Company ") Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment
RNS Number : 7052Z Renalytix AI PLC 25 May 2021 Renalytix AI plc ("Renalytix" or the "Company") Director/PDMR Dealing New York , 25 May 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by James McCullough , the Company's Chief Executive Officer, of 10,462
RNS Number : 4140Z Renalytix AI PLC 21 May 2021 Renalytix AI plc ("Renalytix" or the "Company") Director/PDMR Dealing New York , 21 May 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by James McCullough , the Company's Chief Executive Officer, of 54,538
RNS Number : 1113Z Renalytix AI PLC 19 May 2021 Renalytix AI plc (" RenalytixAI " or the " Company ") ATRIUM HEALTH, WAKE FOREST BAPTIST HEALTH, WAKE FOREST SCHOOL OF MEDICINE AND RENALYTIX PARTNER TO ADVANCE KIDNEY HEALTH Partnership marks a long-term commitment to reducing impact of
RNS Number : 3487W Renalytix AI PLC 22 April 2021 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this
